SCHEMBL7920129

SCHEMBL7920129

C=C(O)c1ccc2cccc(-c3ccccc3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
MPI P34949 1/20 0.40
CDK4 P11802 2/20 0.39
CCND1 P24385 2/20 0.39
MCL1 Q07820 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
F9 P00740 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7917731 0.85 TNF (0.49) TNFCYP1A2MAPTSMN1; SMN2KDM4E
SCHEMBL8755930 0.83 PLA2G2D (0.53) CYP1A2CYP2C9CYP2C19HDAC8HDAC6
SCHEMBL7916817 0.82 AKR1C3 (0.41) CYP1A2CYP2C9CYP2C19HDAC6MAPT
SCHEMBL7918345 0.82 CYP1A2 (0.40) CYP1A2CYP2C19MEN1KMT2ASMN1; SMN2
SCHEMBL1528162 0.81 PLA2G2D (0.54) CYP1A2CYP2C9CYP2C19HDAC8HDAC6
SCHEMBL8755335 0.80 MAPT (0.58) TNFCYP1A2CYP2C9CYP2C19HDAC8
SCHEMBL7918689 0.79 KDM4E (0.45) CYP2C9MAPTMEN1KMT2AMAPK1
SCHEMBL7906709 0.79 CA1 (0.41) CYP1A2CYP2C9CYP2C19MAPTKMT2A
SCHEMBL7917427 0.77 F2 (0.41) TNFHDAC6MAPTKMT2AMAPK1
SCHEMBL16502583 0.77 PLA2G2D (0.50) CYP1A2CYP2C9CYP2C19HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed